SEC Filing Document

Company: Ambitious Entertainment, Inc.
Ticker: 
CIK: 1900851
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-08
Accession Number: 0001493152-25-017387
Exchange: 
SIC Code: 7812
SIC Description: Services-Motion Picture & Video Tape Production
URL: https://www.sec.gov/Archives/edgar/data/1900851/000149315225017387/filename1.htm

Chunk 41 of 63
Word Count: 1354
Character Count: 8618

Document Content:

at those prices less a concession not in excess of $[●] per share. If all of the shares offered by us are not sold at the public offering price, the underwriters may change the offering price and other selling terms by means of a supplement to this prospectus. The following table shows the per share price and total underwriting discounts and commissions to be paid to the underwriters. These amounts are shown assuming both no exercise and full exercise of the underwriters’ over-allotment. Per Share Total Without Over-Allotment Option Total With Full Over-Allotment Option Initial public offering price $ [●] $ [●] $ [●] Underwriting discounts and commissions(1) $ [●] $ [●] $ [●] Proceeds, before expenses, to us $ [●] $ [●] $ [●] (1) Represents an underwriting discount of [●]% of the gross proceeds of the offering, assuming all investors in this offering are introduced by the underwriters.

have agreed to pay all of the expenses relating to the offering, including (a) all filing fees and communication expenses relating to
the registration of the shares of common stock to be sold in this offering with the Securities and Exchange Commission; (b) all fees
and expenses relating to the listing of the shares on the NYSE American and such other exchanges as the Company and Representative together
determine, including any fees charged by DTC; (c) all fees, expenses and disbursements relating to the registration or qualification
of the shares under “blue sky” or securities laws. of such states of the United States of America and other jurisdictions
designated by the Representative, including the reasonable fees and expenses of the Representative’s blue sky counsel; (d) all
fees, expenses and disbursements relating to the registration, qualification or exemption of the shares under the securities laws of
such foreign jurisdictions designated by the Representative; (e) all filing fees incurred in connection with the review of this offering
by the Financial Industry Regulatory Authority, Inc., or FINRA, (f) all fees, expenses and disbursements relating to background checks
of our officers and directors; (g) the costs of all mailing and printing of the underwriting documents as the Representative may reasonably
deem necessary; (h) the fees and expenses of the counsel to the underwriters; (i) the Representative’s actual accountable road
show expenses for the offering, and (j) the Representatives’ cost of mailing prospectuses and any other offering materials to potential
investors; (k) the costs of leather bound volumes and Lucite cube mementos in such quantities as the Representative may reasonably request;
transfer taxes; and transfer and warrant agent and registrar fees; provided that the total of expenses described in clauses (f), (g),
(h), (i), (j) and (k) shall in the aggregate not exceed [●].

have also agreed to pay, at the closing of the offering, a non-accountable expense allowance to the Representative equal to [●]%
of the gross proceeds from the offering (excluding any proceeds received upon any subsequent exercise of the over-allotment option).

estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense
allowance, will be approximately $[●].

Discretionary
Accounts

The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Representative’s
Warrants

have agreed to issue to the Representative or its designees at the closing of this offering warrants to purchase the number of common
stock equal to [●]% of the aggregate number of shares sold in this offering. The warrants will be exercisable at any time and from
time to time, in whole or in part, during the four-and-a-half-year period commencing six months from the commencement of sales in this
offering. The warrants will be exercisable at a per share price equal to [●]% of the initial public offering price per share in
the offering. The warrants provide for registration rights (including a one-time demand registration right at our expense and piggyback
registration rights that, in each case, expire 5 years from the commencement of sales of this offering) and customary anti-dilution provisions
as permitted under FINRA Rule 5110(g)(8).

The
warrants are deemed underwriting compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of
FINRA. The Representative (or permitted assignees under Rule 5110(e)(2)(B)) will not sell, transfer, assign, pledge, or hypothecate these
warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction
that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the
date of this prospectus. The warrants and shares of common stock issuable upon exercise of the warrants are being registered as a part
of the registration statement of which this prospectus forms a part.

The
exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including
in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation.

Right
of First Refusal

Until
the date that is _________ ([●]) months after the closing date of this offering, if we or any of our subsidiaries decide (a) to
finance or refinance any indebtedness using a manager or agent or (b) decides to raise funds by means of a public offering (including
through an at-the-market facility) or a private placement or any other capital-raising financing of equity, equity-linked or debt securities
using an underwriter or placement agent, the Representative shall have the right of first refusal, unless we terminate the underwriting
agreement for cause, which includes the Representative’s material failure to provide the underwriting services contemplated in
the underwriting agreement, to act as sole book-runner, sole manager, sole placement agent or sole agent at the Representative’s
sole discretion, on terms customary to the Representative. The Representative will have the sole right to determine whether any other
broker dealer will have the right to participate in such offering and the economic terms of such participation.

Tail
Fee

have granted the Representative the right, unless we terminate the underwriting agreement for cause, which includes the Representative’s
material failure to provide the underwriting services contemplated in the underwriting agreement, for a period of ________ ([●])
months after the termination or expiration of the Representative’s engagement with us, to receive a cash fee equal to _____ percent
([●]%) of the gross proceeds received by us with respect to any public or private offering or other financing or capital-raising
transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to us by any investor
actually introduced by the Representative to the Company in connection with Tail Financing, provided that such transaction is by a party
actually introduced to us in an offering in which we have direct knowledge of such party’s participation

Lock-Up
Agreements

Pursuant
to “lock-up” agreements, our executive officers and directors, and certain of our stockholders, have agreed, without the
prior written consent of the Representative not to directly or indirectly, offer to sell, sell, pledge or otherwise transfer or dispose
of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or
disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers
to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for
or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any other securities
of the Company or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 180 days
from the date of this prospectus, in the case of our directors and officers, [●] days from the date of this prospectus, in the
case of certain of our principal stockholders.

Sales of Similar Securities